Immuron Acquires Oral Immunotherapy IP from Hadasit in Exchange for Equity

The deal establishes Hadasit, the technology-transfer arm of Hadassah University Medical Center in Israel, as the largest shareholder in Immuron with a 19.99 percent stake.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories